Previous 10 | Next 10 |
A new study has found that patients with COVID-19 given convalescent plasma did not show a survival benefit compared to those on standard of care.The study, which has yet to be peer reviewed, found that there was no difference in 28-day mortality between the two groups.Results also showed tha...
RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived b...
ADMA Biologics' (ADMA) plasma collection center in Kennesaw, Georgia has received approval from the Korean Ministry of Food and Drug Safety ((MFDS)) for the sale of source plasma into South Korea.In addition, ADMA announced the Kennesaw plasma collection center received FDA approval to i...
RAMSEY, N.J. and BOCA RATON, Fla. and KENNESAW, Ga., March 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, tod...
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improv...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...
ADMA Biologics ([[ADMA]] +12.3%) announced the FDA approval for its ADMA BioCenters plasma collection facility located in Knoxville, Tennessee.Having started operations in Q3 2020, the plasma collection center is now licensed to collect human source plasma for further manufacturing in th...
RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, Tenn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, t...
We are trying something new this year where we share and track the 2021 Top Ideas from our Marketplace contributors. We start off with our Tech/Growth and Value stock contributors and highlight two picks that quickly peaked with 70% returns in under two weeks. Next week, we'll sha...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...